Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

Similar articles for PubMed (Select 21653695)

1.

Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.

Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldin E, Moaven N, Sidransky E, Lee JC.

J Biol Chem. 2011 Aug 12;286(32):28080-8. doi: 10.1074/jbc.M111.237859. Epub 2011 Jun 8.

2.

Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.

Yap TL, Jiang Z, Heinrich F, Gruschus JM, Pfefferkorn CM, Barros M, Curtis JE, Sidransky E, Lee JC.

J Biol Chem. 2015 Jan 9;290(2):744-54. doi: 10.1074/jbc.M114.610584. Epub 2014 Nov 26.

PMID:
25429104
3.

Saposin C protects glucocerebrosidase against α-synuclein inhibition.

Yap TL, Gruschus JM, Velayati A, Sidransky E, Lee JC.

Biochemistry. 2013 Oct 15;52(41):7161-3. doi: 10.1021/bi401191v. Epub 2013 Oct 1.

4.

Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.

Dermentzaki G, Dimitriou E, Xilouri M, Michelakakis H, Stefanis L.

PLoS One. 2013 Apr 8;8(4):e60674. doi: 10.1371/journal.pone.0060674. Print 2013.

5.

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.

Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, Schapira AH.

Ann Neurol. 2012 Sep;72(3):455-63. doi: 10.1002/ana.23614.

6.

The association between lysosomal protein glucocerebrosidase and Parkinson's disease.

Kong B, Yang T, Gu JW, Kuang YQ, Cheng L, Yang WT, Yang XK, Xia X, Cheng JM, Ma Y, Zhang JH, Yu SX.

Eur Rev Med Pharmacol Sci. 2013 Jan;17(2):143-51. Retraction in: Eur Rev Med Pharmacol Sci. 2015;19(2):179.

7.

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D.

Cell. 2011 Jul 8;146(1):37-52. doi: 10.1016/j.cell.2011.06.001. Epub 2011 Jun 23.

8.

Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C.

Gruschus JM, Jiang Z, Yap TL, Hill SA, Grishaev A, Piszczek G, Sidransky E, Lee JC.

Biochem Biophys Res Commun. 2015 Feb 20;457(4):561-6. doi: 10.1016/j.bbrc.2015.01.024. Epub 2015 Jan 17.

PMID:
25600808
9.

Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity.

Yap TL, Velayati A, Sidransky E, Lee JC.

Mol Genet Metab. 2013 Jan;108(1):56-64. doi: 10.1016/j.ymgme.2012.11.010. Epub 2012 Nov 28.

10.

Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage.

Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, Wood NW, Hardy J, Mark Cooper J, Schapira AH.

Neurochem Int. 2013 Jan;62(1):1-7. doi: 10.1016/j.neuint.2012.10.010. Epub 2012 Oct 23.

11.

Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.

Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, Pandit D, Tang L, Kornhaber GJ, Hamuro Y, Clarke JT, Mahuran DJ.

J Biol Chem. 2009 Aug 28;284(35):23502-16. doi: 10.1074/jbc.M109.012393. Epub 2009 Jul 3.

12.

Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.

Yang NY, Lee YN, Lee HJ, Kim YS, Lee SJ.

Biol Chem. 2013 Jul;394(7):807-18. doi: 10.1515/hsz-2012-0322. Review.

PMID:
23435096
13.

Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism.

Manning-Boğ AB, Schüle B, Langston JW.

Neurotoxicology. 2009 Nov;30(6):1127-32. doi: 10.1016/j.neuro.2009.06.009. Epub 2009 Jul 2.

PMID:
19576930
14.

Exploring the link between glucocerebrosidase mutations and parkinsonism.

Westbroek W, Gustafson AM, Sidransky E.

Trends Mol Med. 2011 Sep;17(9):485-93. doi: 10.1016/j.molmed.2011.05.003. Epub 2011 Jul 1. Review.

15.

Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.

Fishbein I, Kuo YM, Giasson BI, Nussbaum RL.

Brain. 2014 Dec;137(Pt 12):3235-47. doi: 10.1093/brain/awu291. Epub 2014 Oct 27.

PMID:
25351739
16.

Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice.

Xu YH, Xu K, Sun Y, Liou B, Quinn B, Li RH, Xue L, Zhang W, Setchell KD, Witte D, Grabowski GA.

Hum Mol Genet. 2014 Aug 1;23(15):3943-57. doi: 10.1093/hmg/ddu105. Epub 2014 Mar 5.

PMID:
24599400
17.

Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.

Ron I, Rapaport D, Horowitz M.

Hum Mol Genet. 2010 Oct 1;19(19):3771-81. doi: 10.1093/hmg/ddq292. Epub 2010 Jul 19.

18.

Hypercoagulability, parkinsonism, and Gaucher disease.

Rosenbaum H, Aharon-Peretz J, Brenner B.

Semin Thromb Hemost. 2013 Nov;39(8):928-34. doi: 10.1055/s-0033-1357485. Epub 2013 Oct 15. Review.

PMID:
24129683
19.

Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease.

Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, Waddington SN, Schapira AH, Duchen MR.

Cell Metab. 2013 Jun 4;17(6):941-53. doi: 10.1016/j.cmet.2013.04.014. Epub 2013 May 23.

20.

Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.

Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E.

Acta Neuropathol. 2010 Nov;120(5):641-9. doi: 10.1007/s00401-010-0741-7. Epub 2010 Sep 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk